Literature DB >> 19748323

Liquid chromatography-tandem mass spectrometry method for the quantification of dimebon in rat plasma and brain tissue.

Ramakrishna Nirogi1, Vishwottam Kandikere, Koteshwara Mudigonda, Prashanth Komarneni, Rajeshkumar Boggavarapu.   

Abstract

A sensitive high-performance liquid chromatography-positive ion electrospray tandem mass spectrometry method was developed and validated for the quantification of dimebon in rat plasma and brain tissue. Following liquid-liquid extraction, the analyte was separated using a gradient mobile phase on a reversed phase column and analyzed by MS/MS in the multiple reaction monitoring mode using the respective [M+H](+) ions, m/z 320-277 for dimebon and m/z 407-100 for the internal standard. The assay exhibited a linear dynamic range of 0.25-250 ng/mL for dimebon in rat plasma and brain tissue. Acceptable precision (<11%) and accuracy (100+/-7%) were obtained for concentrations over the standard curve range. A run time of 2.5 min for each sample made it possible to analyze more than 250 samples per day. The method was successfully applied to quantify dimebon concentrations in a rodent pharmacokinetic study. Moreover, it can be believed that the assay method in rat plasma would facilitate the ease of adaptability of dimebon quantification in human plasma for clinical trials.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19748323     DOI: 10.1016/j.jchromb.2009.08.042

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  5 in total

1.  Dimebon alters hippocampal amyloid pathology in 3xTg-AD mice.

Authors:  Sylvia E Perez; Muhammad Nadeem; Katherine R Sadleir; Joanna Matras; Christy M Kelley; Scott E Counts; Robert Vassar; Elliott J Mufson
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2012-09-20

2.  Preclinical study of dimebon on β-amyloid-mediated neuropathology in Alzheimer's disease.

Authors:  Jun Wang; Mario G Ferruzzi; Merina Varghese; Xianjuan Qian; Alice Cheng; Mathew Xie; Wei Zhao; Lap Ho; Giulio M Pasinetti
Journal:  Mol Neurodegener       Date:  2011-01-19       Impact factor: 14.195

3.  Dimebon does not ameliorate pathological changes caused by expression of truncated (1-120) human alpha-synuclein in dopaminergic neurons of transgenic mice.

Authors:  Tatyana A Shelkovnikova; Alexey A Ustyugov; Steven Millership; Owen Peters; Oleg Anichtchik; Maria Grazia Spillantini; Vladimir L Buchman; Sergey O Bachurin; Natalia N Ninkina
Journal:  Neurodegener Dis       Date:  2011-05-12       Impact factor: 2.977

4.  Dimebon slows progression of proteinopathy in γ-synuclein transgenic mice.

Authors:  Sergey O Bachurin; Tatyana A Shelkovnikova; Alexey A Ustyugov; Owen Peters; Ina Khritankova; Marina A Afanasieva; Tatyana V Tarasova; Igor I Alentov; Vladimir L Buchman; Natalia N Ninkina
Journal:  Neurotox Res       Date:  2011-12-17       Impact factor: 3.911

5.  Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses.

Authors:  Ron J Keizer; Robert S Jansen; Hilde Rosing; Bas Thijssen; Jos H Beijnen; Jan H M Schellens; Alwin D R Huitema
Journal:  Pharmacol Res Perspect       Date:  2015-03-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.